What is HC Wainwright’s Estimate for FENC Q3 Earnings?

Adherex Technologies Inc. (NASDAQ:FENC) – Analysts at HC Wainwright decreased their Q3 2026 earnings per share estimates for Adherex Technologies in a report issued on Friday, May 22nd. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn $0.10 per share for the quarter, down from their previous forecast of $0.12. HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for Adherex Technologies’ current full-year earnings is $0.26 per share. HC Wainwright also issued estimates for Adherex Technologies’ Q4 2026 earnings at $0.12 EPS, FY2026 earnings at $0.27 EPS, Q1 2027 earnings at $0.14 EPS, Q2 2027 earnings at $0.20 EPS, Q3 2027 earnings at $0.25 EPS and FY2027 earnings at $0.89 EPS.

Adherex Technologies (NASDAQ:FENC) last released its quarterly earnings data on Thursday, May 14th. The company reported $0.01 EPS for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.03. The business had revenue of $15.11 million during the quarter, compared to the consensus estimate of $13.90 million. Adherex Technologies had a negative return on equity of 43.87% and a negative net margin of 17.12%.

A number of other equities research analysts also recently commented on the company. Wedbush reiterated an “outperform” rating and issued a $13.00 price objective on shares of Adherex Technologies in a report on Thursday, April 16th. Wall Street Zen upgraded Adherex Technologies from a “hold” rating to a “strong-buy” rating in a report on Saturday, May 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Adherex Technologies in a report on Tuesday, April 21st. Zacks Research downgraded Adherex Technologies from a “hold” rating to a “strong sell” rating in a report on Wednesday, March 25th. Finally, B. Riley Financial assumed coverage on Adherex Technologies in a report on Thursday, February 12th. They issued a “buy” rating and a $16.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $15.40.

Adherex Technologies Stock Performance

NASDAQ FENC opened at $9.93 on Monday. The stock has a 50-day simple moving average of $7.12 and a 200 day simple moving average of $7.62. The company has a market capitalization of $342.98 million, a PE ratio of -34.24 and a beta of 0.91. Adherex Technologies has a 12 month low of $5.65 and a 12 month high of $10.45.

Insider Buying and Selling at Adherex Technologies

In other news, Director Rosty Raykov sold 10,946 shares of the company’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $6.31, for a total transaction of $69,069.26. Following the completion of the transaction, the director directly owned 113,856 shares of the company’s stock, valued at $718,431.36. This represents a 8.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.73% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Adherex Technologies stock. AQR Capital Management LLC purchased a new stake in shares of Adherex Technologies Inc. (NASDAQ:FENC) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 10,897 shares of the company’s stock, valued at approximately $66,000. Hedge funds and other institutional investors own 55.51% of the company’s stock.

Key Adherex Technologies News

Here are the key news stories impacting Adherex Technologies this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and $16 price target on Adherex Technologies, signaling confidence in the company’s longer-term growth potential despite the estimate revisions. HC Wainwright Issues Positive Forecast for Adherex Technologies (NASDAQ:FENC) Stock Price
• Positive Sentiment: Recent coverage says PEDMARK is being pushed into a larger adolescent and young adult (AYA) market after a record quarter, which could support revenue growth if adoption expands. Adherex Technologies’ PEDMARK push targets larger AYA market after record quarter
• Neutral Sentiment: HC Wainwright lowered earnings estimates for several upcoming periods, including FY2026, Q1 2027, Q2 2027, Q3 2027, and FY2027. The cuts were modest and the firm kept its bullish rating, so the market may view this as a slight valuation headwind rather than a major concern.

About Adherex Technologies

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014. Fennec Pharmaceuticals Inc was founded in 1996 and is based in Research Triangle Park, North Carolina.